Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Senseonics Holdings, Inc.SENS · Entity 5469 | GC & Corp. Development Advisor | June 15, 2026 | June 17, 2026 |
| VERTEX PHARMACEUTICALS INC / MAVRTX · Entity 2875 | EVP & Chief Legal Officer | November 17, 2014 | November 19, 2014 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Senseonics Holdings, Inc.
Report date June 15, 2026 · Filed June 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 285,512 |
Reported balance
After 2026-06-15 transaction · row 1
1 source rowRow 1 · 2026-06-15 · Tax withholding · Disposed 9,545 · Balance 285,512 F1: Represents shares withheld to satisfy withholding tax obligations upon the vesting of restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares withheld to satisfy withholding tax obligations upon the vesting of restricted stock units.
VERTEX PHARMACEUTICALS INC / MA
Report date November 17, 2014 · Filed November 19, 2014
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 72,053 |
Reported balance
After 2014-11-17 transaction · row 1
1 source rowRow 1 · 2014-11-17 · Gift · Disposed 410 · Balance 72,053 F1: Transaction made pursuant to Mr. Horton's company approved trading plan under Rule 10b5-1. F2: Represents two gifts made to a charity and a charity donor-advised fund. |
| Common StockSEC Table I · non-derivative | Indirect401(k) | 366 |
Reported balance
Holding disclosure · report date 2014-11-17 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 366 |
Filing footnotes · ownership attribution and instrument terms
F1: Transaction made pursuant to Mr. Horton's company approved trading plan under Rule 10b5-1.
F2: Represents two gifts made to a charity and a charity donor-advised fund.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 15, 2026 Filed Jun 17, 2026 20:15 UTC | Senseonics Holdings, Inc. SENS · Entity 5469 | Tax withholdingCommon Stock | 9,545 | $7.18 | $68,533.10 |
DisclosureSEC source: 0001552047-26-000006 · form4-06172026_040614.xml · nonDerivative · entry 1 Horton Kenneth L · CIK 0001552047 · GC & Corp. Development Advisor 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 285,512 F1 · kind: Represents shares withheld to satisfy withholding tax obligations upon the vesting of restricted stock units. Read SEC document |
| May 19, 2026 Filed May 21, 2026 21:41 UTC | Senseonics Holdings, Inc. SENS · Entity 5469 | GrantEmployee Stock Option (right to buy) · Derivative | 217,338 | $0.00 Strike: $5.54 | $0.00 |
DisclosureSEC source: 0001552047-26-000004 · form4-05212026_090529.xml · derivative · entry 2 Horton Kenneth L · CIK 0001552047 · GC & Corp. Development Advisor 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 217,338 Underlying: Common Stock · 217,338 shares Expires 2036-05-18 F3 · derivative.exercise_date: The options vest in 48 equal monthly installments commencing on May 19, 2026, subject to the Reporting Person's continuous service with the Issuer as of the applicable vesting date. Read SEC document |
| May 19, 2026 Filed May 21, 2026 21:41 UTC | Senseonics Holdings, Inc. SENS · Entity 5469 | GrantCommon Stock | 157,943 | $0.00 | $0.00 |
DisclosureSEC source: 0001552047-26-000004 · form4-05212026_090529.xml · nonDerivative · entry 1 Horton Kenneth L · CIK 0001552047 · GC & Corp. Development Advisor 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 295,057 F1 · shares: Represents a restricted stock unit ("RSU") grant. The RSUs vest in eight equal installments with the first installment vesting on June 15, 2026 and the remaining seven installments vesting in six month increments commencing on November 15, 2026, subject to the Reporting Person's continuous service with the Issuer as of the applicable vesting date. F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| May 15, 2026 Filed May 18, 2026 20:30 UTC | Senseonics Holdings, Inc. SENS · Entity 5469 | Tax withholdingCommon Stock | 7,320 | $5.82 | $42,602.40 |
DisclosureSEC source: 0001552047-26-000002 · form4-05182026_040503.xml · nonDerivative · entry 1 Horton Kenneth L · CIK 0001552047 · GC & Corp. Development Advisor 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 137,114 F1 · kind: Represents shares withheld to satisfy withholding tax obligations upon the vesting of restricted stock units. Read SEC document |
| November 15, 2025 Filed Nov 19, 2025 00:00 UTC | Senseonics Holdings, Inc. SENS · Entity 5469 | Tax withholdingCommon Stock | 5,997 | $6.26 | $37,541.22 |
DisclosureSEC source: 0001552047-25-000003 · form4-11182025_071104.xml · nonDerivative · entry 1 Horton Kenneth L · CIK 0001552047 · GC & Corp. Development Advisor 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 144,434 F1 · kind: Represents shares withheld to satisfy withholding tax obligations upon the vesting of restricted stock units. F2 · balance_after: Effective October 17, 2025, the Issuer effected a 1-for-20 reverse stock split of the Issuer's common stock. The number of securities reported herein have been adjusted to reflect the reverse stock split. Read SEC document |
| June 16, 2025 Filed Jun 17, 2025 22:45 UTC | Senseonics Holdings, Inc. SENS · Entity 5469 | Tax withholdingCommon Stock | 35,784 | $0.51 | $18,249.84 |
DisclosureSEC source: 0001415889-25-017599 · form4-06172025_060604.xml · nonDerivative · entry 1 Horton Kenneth L · CIK 0001552047 · GC & Corp. Development Advisor 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,008,622 F1 · kind: Represents shares withheld to satisfy withholding tax obligations upon the vesting of restricted stock units. Read SEC document |
| May 23, 2025 Filed May 28, 2025 20:30 UTC | Senseonics Holdings, Inc. SENS · Entity 5469 | GrantEmployee Stock Option (right to buy) · Derivative | 712,792 | $0.00 Strike: $0.51 | $0.00 |
DisclosureSEC source: 0001415889-25-014713 · form4-05282025_040507.xml · derivative · entry 2 Horton Kenneth L · CIK 0001552047 · GC & Corp. Development Advisor 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 712,792 Underlying: Common Stock · 712,792 shares Expires 2035-05-22 F3 · derivative.exercise_date: The options vest in 48 equal monthly installments commencing on June 23, 2025, subject to the Reporting Person's continuous service with the Issuer as of the applicable vesting date. Read SEC document |
| May 23, 2025 Filed May 28, 2025 20:30 UTC | Senseonics Holdings, Inc. SENS · Entity 5469 | GrantCommon Stock | 505,251 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-014713 · form4-05282025_040507.xml · nonDerivative · entry 1 Horton Kenneth L · CIK 0001552047 · GC & Corp. Development Advisor 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,044,406 F1 · shares: Represents a restricted stock unit ("RSU") grant. The RSUs vest in eight equal installments with the first installment vesting on June 15, 2025 and the remaining seven installments vesting in six month increments commencing on November 15, 2025, subject to the Reporting Person's continuous service with the Issuer as of the applicable vesting date. F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| May 15, 2025 Filed May 19, 2025 22:00 UTC | Senseonics Holdings, Inc. SENS · Entity 5469 | Tax withholdingCommon Stock | 167,085 | $0.55 | $91,896.75 |
DisclosureSEC source: 0001415889-25-013692 · form4-05192025_060507.xml · nonDerivative · entry 1 Horton Kenneth L · CIK 0001552047 · GC & Corp. Development Advisor 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,539,155 F1 · kind: Represents shares withheld to satisfy withholding tax obligations upon the vesting of restricted stock units. Read SEC document |
| November 15, 2024 Filed Nov 18, 2024 21:15 UTC | Senseonics Holdings, Inc. SENS · Entity 5469 | Tax withholdingCommon Stock | 187,665 | $0.28 | $52,546.20 |
DisclosureSEC source: 0001415889-24-027077 · form4-11182024_041107.xml · nonDerivative · entry 1 Horton Kenneth L · CIK 0001552047 · GC & Corp. Development Advisor 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,706,240 F1 · kind: Represents shares withheld to satisfy withholding tax obligations upon the vesting of restricted stock units. Read SEC document |
| June 15, 2024 Filed Jun 18, 2024 20:15 UTC | Senseonics Holdings, Inc. SENS · Entity 5469 | Tax withholdingCommon Stock | 80,785 | $0.39 | $31,506.15 |
DisclosureSEC source: 0001415889-24-017394 · form4-06182024_040625.xml · nonDerivative · entry 1 Horton Kenneth L · CIK 0001552047 · GC & Corp. Development Advisor 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,893,905 F1 · kind: Represents shares withheld to satisfy withholding tax obligations upon the vesting of restricted stock units. Read SEC document |
| May 23, 2024 Filed May 24, 2024 20:46 UTC | Senseonics Holdings, Inc. SENS · Entity 5469 | GrantCommon Stock | 1,135,604 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-014544 · form4-05242024_040543.xml · nonDerivative · entry 1 Horton Kenneth L · CIK 0001552047 · GC & Corp. Development Advisor 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,974,690 F1 · shares: Represents a restricted stock unit ("RSU") grant. The RSUs vest in eight equal installments with the first installment vesting on June 15, 2024 and the remaining seven installments vesting in six month increments commencing on November 15, 2024, subject to the Reporting Person's continuous service with the Issuer as of the applicable vesting date. F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| May 15, 2024 Filed May 17, 2024 20:15 UTC | Senseonics Holdings, Inc. SENS · Entity 5469 | Tax withholdingCommon Stock | 108,100 | $0.50 | $54,050.00 |
DisclosureSEC source: 0001415889-24-013482 · form4-05172024_040516.xml · nonDerivative · entry 1 Horton Kenneth L · CIK 0001552047 · GC & Corp. Development Advisor 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,839,086 F1 · kind: Represents shares withheld to satisfy withholding tax obligations upon the vesting of restricted stock units. Read SEC document |
| November 15, 2023 Filed Nov 17, 2023 21:56 UTC | Senseonics Holdings, Inc. SENS · Entity 5469 | Tax withholdingCommon Stock | 163,319 | $0.61 | $99,624.59 |
DisclosureSEC source: 0001209191-23-055774 · doc4.xml · nonDerivative · entry 1 Horton Kenneth L · CIK 0001552047 · GC & Corp. Development Advisor 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,947,186 F1 · kind: Represents shares withheld to satisfy withholding tax obligations upon the vesting of restricted stock units. Read SEC document |
| June 15, 2023 Filed Jun 20, 2023 22:12 UTC | Senseonics Holdings, Inc. SENS · Entity 5469 | Tax withholdingCommon Stock | 51,276 | $0.77 | $39,482.52 |
DisclosureSEC source: 0001209191-23-038581 · doc4.xml · nonDerivative · entry 1 Horton Kenneth L · CIK 0001552047 · GC & Corp. Development Advisor 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,110,505 F1 · kind: Represents shares withheld to satisfy withholding tax obligations upon the vesting of restricted stock units. Read SEC document |
| May 15, 2023 Filed May 18, 2023 00:49 UTC | Senseonics Holdings, Inc. SENS · Entity 5469 | GrantCommon Stock | 782,089 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-030451 · doc4.xml · nonDerivative · entry 4 Horton Kenneth L · CIK 0001552047 · GC & Corp. Development Advisor 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,161,781 F2 · shares: Represents an RSU grant. The RSUs vest in eight equal installments with the first installment vesting on June 15, 2023 and the remaining seven installments vesting in six month increments commencing on November 15, 2023, subject to the Reporting Person's continuous service with the Issuer as of the applicable vesting date. F3 · price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| May 15, 2023 Filed May 18, 2023 00:49 UTC | Senseonics Holdings, Inc. SENS · Entity 5469 | Tax withholdingCommon Stock | 137,927 | $0.74 | $102,065.98 |
DisclosureSEC source: 0001209191-23-030451 · doc4.xml · nonDerivative · entry 3 Horton Kenneth L · CIK 0001552047 · GC & Corp. Development Advisor 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,379,692 F1 · kind: Represents shares withheld to satisfy withholding tax obligations upon the vesting of restricted stock units ("RSUs"). Read SEC document |
| November 15, 2022 Filed May 18, 2023 00:49 UTC | Senseonics Holdings, Inc. SENS · Entity 5469 | Tax withholdingCommon Stock | 104,306 | $1.25 | $130,382.50 |
DisclosureSEC source: 0001209191-23-030451 · doc4.xml · nonDerivative · entry 2 Horton Kenneth L · CIK 0001552047 · GC & Corp. Development Advisor 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,517,619 F1 · kind: Represents shares withheld to satisfy withholding tax obligations upon the vesting of restricted stock units ("RSUs"). Read SEC document |
| June 15, 2022 Filed May 18, 2023 00:49 UTC | Senseonics Holdings, Inc. SENS · Entity 5469 | Tax withholdingCommon Stock | 26,105 | $0.97 | $25,321.85 |
DisclosureSEC source: 0001209191-23-030451 · doc4.xml · nonDerivative · entry 1 Horton Kenneth L · CIK 0001552047 · GC & Corp. Development Advisor 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,621,925 F1 · kind: Represents shares withheld to satisfy withholding tax obligations upon the vesting of restricted stock units ("RSUs"). Read SEC document |
| May 26, 2022 Filed May 31, 2022 22:20 UTC | Senseonics Holdings, Inc. SENS · Entity 5469 | GrantCommon Stock | 431,035 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-032953 · doc4.xml · nonDerivative · entry 2 Horton Kenneth L · CIK 0001552047 · GC & Corp. Development Advisor 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,648,030 F3 · shares: Represents an RSU grant. The RSUs vest in eight equal installments with the first installment vesting on June 15, 2022 and the remaining seven installments vesting in six month increments commencing on November 15, 2022, subject to the Reporting Person's continuous service with the Issuer as of the applicable vesting date. F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| May 26, 2022 Filed May 31, 2022 22:20 UTC | Senseonics Holdings, Inc. SENS · Entity 5469 | GrantCommon Stock | 45,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-032953 · doc4.xml · nonDerivative · entry 1 Horton Kenneth L · CIK 0001552047 · GC & Corp. Development Advisor 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,216,995 F1 · shares: Represents a Restricted Stock Unit ("RSU") grant. The RSUs vest on May 15, 2023, subject to the Reporting Person's continuous service with the Issuer as of the applicable vesting date. F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| May 16, 2022 Filed May 19, 2022 00:06 UTC | Senseonics Holdings, Inc. SENS · Entity 5469 | Tax withholdingCommon Stock | 45,430 | $1.13 | $51,335.90 |
DisclosureSEC source: 0001209191-22-030280 · doc4.xml · nonDerivative · entry 1 Horton Kenneth L · CIK 0001552047 · GC & Corp. Development Advisor 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,171,995 F1 · kind: Represents shares withheld to satisfy withholding tax obligations upon the vesting of restricted stock units. Read SEC document |
| February 11, 2022 Filed Feb 15, 2022 00:45 UTC | Senseonics Holdings, Inc. SENS · Entity 5469 | SaleCommon Stock | 143,126 | $2.46 | $352,089.96 |
DisclosureSEC source: 0001209191-22-009555 · doc4.xml · nonDerivative · entry 2 Horton Kenneth L · CIK 0001552047 · GC & Corp. Development Advisor 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,217,425 F2 · kind: Represents shares sold to cover tax obligations upon the vesting of RSUs. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.10 to $2.575 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 10, 2022 Filed Feb 15, 2022 00:45 UTC | Senseonics Holdings, Inc. SENS · Entity 5469 | GrantCommon Stock | 255,287 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-009555 · doc4.xml · nonDerivative · entry 1 Horton Kenneth L · CIK 0001552047 · GC & Corp. Development Advisor 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,360,551 F1 · shares: Represents a performance-based restricted stock unit ("RSU") award, which represent a contingent right to receive one share of the Issuer's common stock and vest upon the achievement of certain performance targets, subject to the Reporting Person's continuous service through the vesting events. 100% of the RSUs vested on February 10, 2022 upon the achievement of the performance vesting criteria. Read SEC document |
| November 15, 2021 Filed Nov 18, 2021 14:26 UTC | Senseonics Holdings, Inc. SENS · Entity 5469 | Tax withholdingCommon Stock | 46,426 | $3.80 | $176,418.80 |
DisclosureSEC source: 0001209191-21-065382 · doc4.xml · nonDerivative · entry 1 Horton Kenneth L · CIK 0001552047 · GC & Corp. Development Advisor 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,105,264 F1 · kind: Represents shares withheld to satisfy withholding tax obligations upon the vesting of restricted stock units. Read SEC document |
| June 15, 2021 Filed Jun 16, 2021 22:15 UTC | Senseonics Holdings, Inc. SENS · Entity 5469 | Tax withholdingCommon Stock | 10,899 | $3.69 | $40,217.31 |
DisclosureSEC source: 0001209191-21-041048 · doc4.xml · nonDerivative · entry 1 Horton Kenneth L · CIK 0001552047 · GC & Corp. Development Advisor 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,151,690 F1 · kind: Represents shares withheld to satisfy withholding tax obligations upon the vesting of restricted stock units. Read SEC document |
| May 25, 2021 Filed May 28, 2021 01:33 UTC | Senseonics Holdings, Inc. SENS · Entity 5469 | GrantCommon Stock | 306,451 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-036389 · doc4.xml · nonDerivative · entry 2 Horton Kenneth L · CIK 0001552047 · GC & Corp. Development Advisor 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,162,589 F2 · shares: Represents a RSU grant. The RSUs vest in eight equal installments with the first installment vesting on June 15, 2021 and the remaining RSUs vesting in six month increments commencing on November 15, 2021, subject to the Reporting Person's continuous service with the Issuer as of the applicable vesting date. F3 · price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| May 15, 2021 Filed May 28, 2021 01:33 UTC | Senseonics Holdings, Inc. SENS · Entity 5469 | Tax withholdingCommon Stock | 34,710 | $1.92 | $66,643.20 |
DisclosureSEC source: 0001209191-21-036389 · doc4.xml · nonDerivative · entry 1 Horton Kenneth L · CIK 0001552047 · GC & Corp. Development Advisor 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 856,138 F1 · shares: Represents shares withheld to satisfy withholding tax obligations upon the vesting of restricted stock units ("RSUs"). Read SEC document |
| November 17, 2014 Filed Nov 19, 2014 21:20 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GiftCommon Stock | 410 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-14-070000 · doc4.xml · nonDerivative · entry 1 Horton Kenneth L · CIK 0001552047 · EVP & Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,053 F1 · kind: Transaction made pursuant to Mr. Horton's company approved trading plan under Rule 10b5-1. F2 · shares: Represents two gifts made to a charity and a charity donor-advised fund. Read SEC document |
| October 30, 2014 Filed Nov 3, 2014 22:43 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 40,000 | $0.01 | $400.00 |
DisclosureSEC source: 0001209191-14-065909 · doc4.xml · nonDerivative · entry 1 Horton Kenneth L · CIK 0001552047 · EVP & Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,463 F1 · shares: Performance-based retention award that will vest if performance objectives are achieved prior to November 15, 2019. The award will vest on October 30, 2017 (or, if later, the day following the earnings release for the third quarter of 2017) if the Company achieves positive EBITDA for the 12-month period ending September 30, 2017. Between January 1, 2018 and November 15, 2019, if the Company achieves positive EBITDA for a 12-month period ending on a calendar quarter, the award will vest on the day following the applicable earnings release. Read SEC document |
| September 30, 2014 Filed Oct 1, 2014 21:18 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (right to buy) · Derivative | 36,000 | $0.00 Strike: $55.83 | $0.00 |
DisclosureSEC source: 0001209191-14-060597 · doc4.xml · derivative · entry 7 Horton Kenneth L · CIK 0001552047 · EVP & Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,000 Underlying: Common Stock · 36,000 shares Expires 2022-06-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The option vests in 16 quarterly installments from 06/11/2012. Read SEC document |
| September 30, 2014 Filed Oct 1, 2014 21:18 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 7,400 | $113.91 | $842,934.00 |
DisclosureSEC source: 0001209191-14-060597 · doc4.xml · nonDerivative · entry 5 Horton Kenneth L · CIK 0001552047 · EVP & Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,463 F1 · kind: Transaction made pursuant to Mr. Horton's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Horton undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $113.91 (range $113.62 to $114.41). Read SEC document |
| September 30, 2014 Filed Oct 1, 2014 21:18 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 9,601 | $113.10 | $1,085,873.10 |
DisclosureSEC source: 0001209191-14-060597 · doc4.xml · nonDerivative · entry 4 Horton Kenneth L · CIK 0001552047 · EVP & Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,863 F1 · kind: Transaction made pursuant to Mr. Horton's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Horton undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $113.10 (range $112.61 to $113.60). Read SEC document |
| September 30, 2014 Filed Oct 1, 2014 21:18 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 14,286 | $112.22 | $1,603,174.92 |
DisclosureSEC source: 0001209191-14-060597 · doc4.xml · nonDerivative · entry 3 Horton Kenneth L · CIK 0001552047 · EVP & Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,464 F1 · kind: Transaction made pursuant to Mr. Horton's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Horton undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $112.22 (range $111.61 to $112.60). Read SEC document |
| September 30, 2014 Filed Oct 1, 2014 21:18 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 4,713 | $111.33 | $524,698.29 |
DisclosureSEC source: 0001209191-14-060597 · doc4.xml · nonDerivative · entry 2 Horton Kenneth L · CIK 0001552047 · EVP & Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,750 F1 · kind: Transaction made pursuant to Mr. Horton's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $111.33 (range $110.61 to $111.60). F3 · price: Mr. Horton undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| September 30, 2014 Filed Oct 1, 2014 21:18 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 36,000 | $55.83 | $2,009,880.00 |
DisclosureSEC source: 0001209191-14-060597 · doc4.xml · nonDerivative · entry 1 Horton Kenneth L · CIK 0001552047 · EVP & Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,463 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 15, 2014 Filed Jul 17, 2014 22:23 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantEmployee Stock Option (right to buy) · Derivative | 34,000 | $0.00 Strike: $96.87 | $0.00 |
DisclosureSEC source: 0001209191-14-047899 · doc4.xml · derivative · entry 1 Horton Kenneth L · CIK 0001552047 · EVP & Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,000 Underlying: Common Stock · 34,000 shares Expires 2024-07-14 F1 · derivative.exercise_date: The option vests in 16 quarterly installments from 07/15/2014. Read SEC document |
| July 01, 2014 Filed Jul 3, 2014 20:42 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (right to buy) · Derivative | 28,321 | $0.00 Strike: $45.11 | $0.00 |
DisclosureSEC source: 0001209191-14-046017 · doc4.xml · derivative · entry 5 Horton Kenneth L · CIK 0001552047 · EVP & Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,304 Underlying: Common Stock · 28,321 shares Expires 2023-02-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan, vesting in 16 quarterly installments from 02/05/2013. Read SEC document |
| July 01, 2014 Filed Jul 3, 2014 20:42 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 27,877 | $95.28 | $2,656,120.56 |
DisclosureSEC source: 0001209191-14-046017 · doc4.xml · nonDerivative · entry 3 Horton Kenneth L · CIK 0001552047 · EVP & Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,463 F1 · kind: Transaction made pursuant to Mr. Horton's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Horton undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $95.28 (range $94.79 to $95.66). Read SEC document |
| July 01, 2014 Filed Jul 3, 2014 20:42 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 2,257 | $94.49 | $213,263.93 |
DisclosureSEC source: 0001209191-14-046017 · doc4.xml · nonDerivative · entry 2 Horton Kenneth L · CIK 0001552047 · EVP & Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,340 F1 · kind: Transaction made pursuant to Mr. Horton's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $94.49 (range $93.79 to $94.78). F3 · price: Mr. Horton undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| July 01, 2014 Filed Jul 3, 2014 20:42 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 28,321 | $45.11 | $1,277,560.31 |
DisclosureSEC source: 0001209191-14-046017 · doc4.xml · nonDerivative · entry 1 Horton Kenneth L · CIK 0001552047 · EVP & Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,597 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 05, 2014 Filed Feb 7, 2014 21:04 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantEmployee Stock Option (right to buy) · Derivative | 51,000 | $0.00 Strike: $77.31 | $0.00 |
DisclosureSEC source: 0001209191-14-008354 · doc4.xml · derivative · entry 3 Horton Kenneth L · CIK 0001552047 · EVP & Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,000 Underlying: Common Stock · 51,000 shares Expires 2024-02-04 F2 · derivative.exercise_date: The option vests in 16 quarterly installments from 02/05/2014. Read SEC document |
| February 05, 2014 Filed Feb 7, 2014 21:04 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 17,250 | $0.01 | $172.50 |
DisclosureSEC source: 0001209191-14-008354 · doc4.xml · nonDerivative · entry 1 Horton Kenneth L · CIK 0001552047 · EVP & Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,874 F1 · shares: Stock grant under 2006 Stock and Option Plan, vesting on 2/5/2018, subject to (i) acceleration of 50% of shares upon (a) reaching a specified net product sales level over a one-year period for a combination regimen that includes ivacaftor and a CFTR corrector or (b) dosing of the first patient in the first clinical trial to evaluate a second-generation CFTR corrector compound and (ii) acceleration of 50% of shares upon (a) dosing of the first patient in a pivotal trial for a regimen including VX-661 or a specified cancer compound or (b) reaching a specified net product sales level over a one-year period for all our products. Read SEC document |
| December 12, 2013 Filed Dec 12, 2013 22:49 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 4,532 | $65.46 | $296,664.72 |
DisclosureSEC source: 0001209191-13-056696 · doc4.xml · nonDerivative · entry 1 Horton Kenneth L · CIK 0001552047 · EVP & Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,624 F1 · kind: Transaction made pursuant to Mr. Horton's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $65.46 (range $65.05 to $65.91). F3 · price: Mr. Horton undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| July 30, 2013 Filed Aug 1, 2013 20:10 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 34,000 | $0.00 Strike: $83.36 | $0.00 |
DisclosureSEC source: 0001209191-13-038681 · doc4.xml · derivative · entry 1 Horton Kenneth L · CIK 0001552047 · EVP & Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,000 Underlying: Common Stock · 34,000 shares Expires 2023-07-29 F1 · derivative.exercise_date: The option vests in 16 quarterly installments from 07/30/2013. Read SEC document |
| July 08, 2013 Filed Jul 10, 2013 20:44 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 300 | $81.82 | $24,546.00 |
DisclosureSEC source: 0001209191-13-036101 · doc4.xml · nonDerivative · entry 2 Horton Kenneth L · CIK 0001552047 · EVP & Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,676 F1 · kind: Transaction made pursuant to Mr. Horton's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Horton undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $81.82 (range $81.61 to $82.19). Read SEC document |
| July 08, 2013 Filed Jul 10, 2013 20:44 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,513 | $80.50 | $121,796.50 |
DisclosureSEC source: 0001209191-13-036101 · doc4.xml · nonDerivative · entry 1 Horton Kenneth L · CIK 0001552047 · EVP & Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,976 F1 · kind: Transaction made pursuant to Mr. Horton's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $80.50 (range $80.17 to $80.84). F3 · price: Mr. Horton undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| February 05, 2013 Filed Feb 7, 2013 22:31 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantEmployee Stock Option (right to buy) · Derivative | 90,625 | $0.00 Strike: $45.11 | $0.00 |
DisclosureSEC source: 0001209191-13-007125 · doc4.xml · derivative · entry 2 Horton Kenneth L · CIK 0001552047 · EVP & Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,625 Underlying: Common Stock · 90,625 shares Expires 2023-02-04 F2 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan, vesting in 16 quarterly installments from 02/05/2013. Read SEC document |
| February 05, 2013 Filed Feb 7, 2013 22:31 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 12,084 | $0.01 | $120.84 |
DisclosureSEC source: 0001209191-13-007125 · doc4.xml · nonDerivative · entry 1 Horton Kenneth L · CIK 0001552047 · EVP & Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,751 F1 · shares: Stock grant under 2006 Stock and Option Plan, vesting on 2/5/2017, subject to (i) acceleration of 50% of shares upon (a) receiving filing confirmation for an NDA for a combination regimen that includes both ivacaftor and a corrector compound or (b) receiving filing confirmation for an sNDA that would increase the number of patients with CF eligible for ivacaftor monotherapy, and (ii) acceleration of 50% of shares upon (a) the announcement of proof-of-concept data for a drug candidate other than an HCV, cystic fibrosis, influenza or JAK3 inhibition drug candidate or (b) reaching a specified net sales level over a twelve month period for our CF products. Read SEC document |
| June 11, 2012 Filed Jun 13, 2012 19:52 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantEmployee Stock Option (right to buy) · Derivative | 72,000 | $0.00 Strike: $55.83 | $0.00 |
DisclosureSEC source: 0001209191-12-033675 · doc4.xml · derivative · entry 2 Horton Kenneth L · CIK 0001552047 · EVP & Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,000 Underlying: Common Stock · 72,000 shares Expires 2022-06-10 F2 · derivative.exercise_date: The option vests in 16 quarterly installments beginning on 9/11/2012. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.